ArticleFrontiers in bioinformatics2026
A vasculogenic mimicry subtype unveiled by integrated multi-omics predicts prognosis and guides immunotherapy in MIBC.
Article in Frontiers in bioinformatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The progression, recurrence, and metastasis of muscle-invasive bladder cancer (MIBC) are closely associated with vasculogenic mimicry (VM). Establishing a VM-based molecular subtyping system and clarifying its regulatory network are essential to overcome current therapeutic limitations in MIBC. Methods: This study collected 1,489 previously reported VM-related genes and identified differentially expressed genes between tumor cells and endothelial cells using single-cell transcriptomic analysis. The intersection of these gene sets yielded VM-related genes, of which 12 were selected to construct a prognostic model validated by multi-omics data, including bulk transcriptomic, genomic, mass cytometry, spatial transcriptomic, and metabolomic datasets. Single-cell and bulk RNA sequencing data were integrated to develop a VM-based molecular subtyping system. Results: MIBC patients were classified into three subtypes: VM, Mixed-VM, and Non-VM, each showing distinct prognostic outcomes consistently validated across multiple independent cohorts. The VM subtype demonstrated the most aggressive clinical behavior, characterized by high cellular plasticity and extensive metabolic reprogramming. Compared to the Non-VM subtype, VM-subtype patients exhibited an immunosuppressive tumor microenvironment and elevated tumor mutational burden (TMB), indicating a potentially favorable response to immunotherapy. Combined treatment with the MEK inhibitor TAK-733 and immune checkpoint inhibitors was proposed as a promising therapeutic strategy for this subgroup. Conclusion: This novel VM-based molecular subtyping system for MIBC shows strong potential for clinical application in prognosis prediction, immunotherapy response evaluation, and targeted drug discovery, providing a framework to guide personalized treatment strategies for MIBC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.